Education
About Us
Working with TipRanks
Follow Us
Elicera Therapeutics AB (DE:8E8)
FRANKFURT:8E8
8E8 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.05 - €0.32
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€19.11M
Enterprise Value€32.21M
Total Cash (Recent Filing)kr29.38M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.76
Next Earnings
Apr 29, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding48,535,545
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)118624.60
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
8E8 FAQ
What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was €0.05 and its highest was €0.32 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is €19.11M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
Elicera Therapeutics AB’s upcoming earnings report date is Apr 29, 2025 which is tomorrow.
How were Elicera Therapeutics AB’s earnings last quarter?
Elicera Therapeutics AB released its earnings results on Feb 13, 2025. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.
Is Elicera Therapeutics AB overvalued?
According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 48,535,545 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Elicera Therapeutics AB reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in DE:8E8
---
Company Description
Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.
---
Technical Analysis
Medivir AB
―
Alligator Bioscience AB
―
Biosergen AB
―
Active Biotech AB
―
CombiGene AB
―
---